ZK-283197
Clinical data | |
---|---|
Other names | BAY 86-5310; SH-T04211C |
Routes of administration | By mouth[1] |
Drug class | Estrogen; Selective ERβ agonist |
Identifiers | |
CAS Number |
ZK-283197 (also known as BAY 86-5310 or SH-T04211C) is a selective and orally active ERβ agonist which was under development by Bayer Healthcare AG for the treatment of vasomotor symptoms.[1][2] It reached phase II clinical trials prior to the discontinuation of its development.[1] Its development was terminated in 2014.[1]
References
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.